Phase 3
Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis
Immunovant, batoclimab, myasthenia gravis, Phase 3 success, IMVT-1402, FcRn inhibitor, autoimmune disorders
Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge
Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation
Tris Pharma’s Cebranopadol Shows Promising Results in Phase 3 Trial for Moderate-to-Severe Acute Pain Treatment
Cebranopadol, Tris Pharma, ALLEVIATE-1, Phase 3 Clinical Trial, Acute Pain Treatment, Dual-NMR Agonist, Opioid Crisis, Pain Management
BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025
BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.
Viridian’s Veligrotug Demonstrates Efficacy in Second Pivotal Study for Thyroid Eye Disease
Thyroid Eye Disease, Veligrotug, Viridian Therapeutics, Phase 3 Clinical Trial, THRIVE-2, IGF-1R Antibody
Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer
IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy
Compass Pathways Delays Phase 3 Psilocybin Trials, Cuts 30% of Workforce to Conserve Cash
Compass Pathways, psilocybin trials, Phase 3 delays, workforce reduction, cash conservation, psychedelic drug development
Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis
Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment
Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition